Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:AKT3-SDCCAG8

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: AKT3-SDCCAG8
	FusionPDB ID: 3507
	FusionGDB2.0 ID: 3507
		Hgene	Tgene
	Gene symbol	AKT3	SDCCAG8
	Gene ID	10000	10806
	Gene name	AKT serine/threonine kinase 3	SHH signaling and ciliogenesis regulator SDCCAG8
	Synonyms	MPPH\|MPPH2\|PKB-GAMMA\|PKBG\|PRKBG\|RAC-PK-gamma\|RAC-gamma\|STK-2	BBS16\|CCCAP\|CCCAP SLSN7\|HSPC085\|NPHP10\|NY-CO-8\|SLSN7\|hCCCAP
	Cytomap	1q43-q44	1q43-q44
	Type of gene	protein-coding	protein-coding
	Description	RAC-gamma serine/threonine-protein kinasePKB gammaRAC-gamma serine/threonine protein kinasev-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)	serologically defined colon cancer antigen 8Bardet-Biedl syndrome 16antigen NY-CO-8centrosomal colon cancer autoantigen proteinnephrocystin 10
	Modification date	20200313	20200313
	UniProtAcc	Q9Y243 Main function of 5'-partner protein: FUNCTION: AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. {ECO:0000269\|PubMed:18524868, ECO:0000269\|PubMed:21191416}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000263826, ENST00000336199, ENST00000366539, ENST00000366540, ENST00000492957,	ENST00000496361, ENST00000343783, ENST00000355875, ENST00000366541, ENST00000391846,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	18 X 15 X 7=1890	22 X 19 X 10=4180
	# samples	21	26
	** MAII score	log2(21/1890*10)=-3.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(26/4180*10)=-4.00691941393979 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: AKT3 [Title/Abstract] AND SDCCAG8 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: AKT3 [Title/Abstract] AND SDCCAG8 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	AKT3(243652316)-SDCCAG8(243652442), # samples:2
Anticipated loss of major functional domain due to fusion event.	AKT3-SDCCAG8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AKT3-SDCCAG8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. AKT3-SDCCAG8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. AKT3-SDCCAG8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. AKT3-SDCCAG8 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. AKT3-SDCCAG8 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. AKT3-SDCCAG8 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	AKT3	GO:0043536	positive regulation of blood vessel endothelial cell migration	28254819
Hgene	AKT3	GO:1905564	positive regulation of vascular endothelial cell proliferation	28254819

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:243652316/chr1:243652442)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across AKT3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across SDCCAG8 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000336199	AKT3	chr1	243858893	-	ENST00000355875	SDCCAG8	chr1	243468015	+	2006	238	196	1704	502
ENST00000336199	AKT3	chr1	243858893	-	ENST00000366541	SDCCAG8	chr1	243468015	+	2012	238	196	1704	502
ENST00000336199	AKT3	chr1	243858893	-	ENST00000343783	SDCCAG8	chr1	243468015	+	2010	238	196	1704	502
ENST00000336199	AKT3	chr1	243858893	-	ENST00000391846	SDCCAG8	chr1	243468015	+	646	238	196	645	150
ENST00000366539	AKT3	chr1	243858893	-	ENST00000355875	SDCCAG8	chr1	243468015	+	2141	373	331	1839	502
ENST00000366539	AKT3	chr1	243858893	-	ENST00000366541	SDCCAG8	chr1	243468015	+	2147	373	331	1839	502
ENST00000366539	AKT3	chr1	243858893	-	ENST00000343783	SDCCAG8	chr1	243468015	+	2145	373	331	1839	502
ENST00000366539	AKT3	chr1	243858893	-	ENST00000391846	SDCCAG8	chr1	243468015	+	781	373	331	780	150

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000336199	ENST00000355875	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.003027422	0.99697256
ENST00000336199	ENST00000366541	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.002996977	0.997003
ENST00000336199	ENST00000343783	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.002955985	0.997044
ENST00000336199	ENST00000391846	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.011088254	0.98891175
ENST00000366539	ENST00000355875	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.003680591	0.9963194
ENST00000366539	ENST00000366541	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.003639832	0.9963601
ENST00000366539	ENST00000343783	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.003608092	0.99639195
ENST00000366539	ENST00000391846	AKT3	chr1	243858893	-	SDCCAG8	chr1	243468015	+	0.011352838	0.98864716

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AKT3-SDCCAG8

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
AKT3	chr1	243858893	SDCCAG8	chr1	243468015	238	14	WIYLIPSTTFQWQEKLKLTYEEKCEI
AKT3	chr1	243858893	SDCCAG8	chr1	243468015	373	14	WIYLIPSTTFQWQEKLKLTYEEKCEI

Top

Potential FusionNeoAntigen Information of AKT3-SDCCAG8 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

AKT3-SDCCAG8_243858893_243468015.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:01	WQEKLKLTY	0.9957	0.762	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:17	TTFQWQEKL	0.9825	0.9335	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:16	TTFQWQEKL	0.9821	0.9252	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:24	FQWQEKLKL	0.9684	0.5963	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:30	FQWQEKLKL	0.9684	0.5963	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:67	FQWQEKLKL	0.9684	0.5963	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:21	FQWQEKLKL	0.9669	0.7151	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:60	FQWQEKLKL	0.9655	0.6122	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B57:03	TTFQWQEKL	0.9642	0.9952	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:22	FQWQEKLKL	0.9605	0.6386	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:04	FQWQEKLKL	0.9502	0.7658	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:24	FQWQEKLKL	0.941	0.5621	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B14:02	FQWQEKLKL	0.9296	0.7441	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B14:01	FQWQEKLKL	0.9296	0.7441	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:16	FQWQEKLKL	0.8759	0.5372	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:25	WQEKLKLTY	0.8747	0.8992	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:29	FQWQEKLKL	0.8367	0.5988	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:20	FQWQEKLKL	0.8151	0.6026	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B13:02	FQWQEKLKL	0.8034	0.677	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:02	WQEKLKLTY	0.7783	0.9225	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:01	FQWQEKLKL	0.7524	0.9632	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:01	WQEKLKLTY	0.7159	0.8532	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B38:01	FQWQEKLKL	0.7142	0.9835	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:13	FQWQEKLKL	0.6645	0.9577	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B38:02	FQWQEKLKL	0.661	0.9876	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B47:01	FQWQEKLKL	0.6141	0.5733	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:03	FQWQEKLKL	0.6116	0.8945	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B13:01	FQWQEKLKL	0.5995	0.9843	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A32:13	TTFQWQEKL	0.5344	0.945	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:10	FQWQEKLKL	0.5182	0.6962	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B52:01	TTFQWQEKL	0.4373	0.9811	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:37	FQWQEKLKL	0.3762	0.64	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:03	WQEKLKLTY	0.3646	0.6773	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:18	WQEKLKLTY	0.3361	0.6004	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:19	FQWQEKLKL	0.3361	0.5594	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B13:01	TTFQWQEKL	0.2442	0.9895	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B52:01	FQWQEKLKL	0.0837	0.9629	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B48:01	TFQWQEKLKL	0.4573	0.6431	8	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B13:01	TFQWQEKLKL	0.221	0.9912	8	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:01	FQWQEKLKLTY	1	0.8179	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:25	FQWQEKLKLTY	0.9988	0.9211	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:03	FQWQEKLKLTY	0.9954	0.7853	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B48:01	TTFQWQEKLKL	0.7374	0.6831	7	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C15:06	TTFQWQEKL	0.9975	0.8649	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:08	TTFQWQEKL	0.9973	0.9408	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C15:04	TTFQWQEKL	0.9966	0.8313	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:07	TTFQWQEKL	0.995	0.9709	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C04:14	FQWQEKLKL	0.9714	0.8944	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:01	FQWQEKLKL	0.9684	0.5963	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:07	FQWQEKLKL	0.9669	0.6094	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:05	FQWQEKLKL	0.9643	0.6156	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C06:03	FQWQEKLKL	0.9584	0.9927	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C04:06	FQWQEKLKL	0.9583	0.9334	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:07	FQWQEKLKL	0.9495	0.986	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:19	FQWQEKLKL	0.9469	0.9935	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:29	FQWQEKLKL	0.9147	0.9668	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:13	FQWQEKLKL	0.912	0.9587	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C08:13	FQWQEKLKL	0.9097	0.9699	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C08:04	FQWQEKLKL	0.9097	0.9699	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:46	FQWQEKLKL	0.9048	0.9461	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:10	FQWQEKLKL	0.9018	0.9816	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:80	FQWQEKLKL	0.8998	0.9783	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:67	FQWQEKLKL	0.8998	0.9783	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:05	FQWQEKLKL	0.874	0.9859	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C08:03	FQWQEKLKL	0.8589	0.989	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:04	FQWQEKLKL	0.8223	0.9315	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:14	FQWQEKLKL	0.8053	0.9874	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:09	FQWQEKLKL	0.8041	0.6818	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:21	WQEKLKLTY	0.7878	0.8755	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:27	FQWQEKLKL	0.7828	0.9805	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:12	FQWQEKLKL	0.7695	0.9628	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:08	FQWQEKLKL	0.7668	0.936	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:05	WQEKLKLTY	0.7643	0.8441	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:95	FQWQEKLKL	0.7584	0.8457	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C02:06	FQWQEKLKL	0.7318	0.939	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:04	WQEKLKLTY	0.6981	0.7798	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C12:16	FQWQEKLKL	0.6766	0.9703	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:31	WQEKLKLTY	0.6568	0.8604	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:05	FQWQEKLKL	0.6285	0.9597	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C12:04	TTFQWQEKL	0.5906	0.9922	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C06:03	TTFQWQEKL	0.5826	0.9931	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B14:03	FQWQEKLKL	0.3523	0.7933	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C02:06	TTFQWQEKL	0.3231	0.9574	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:05	FQWQEKLKL	0.3101	0.9513	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B51:07	FQWQEKLKL	0.054	0.8356	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:05	QWQEKLKLTY	0.8311	0.8689	10	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:07	FQWQEKLKLTY	0.9999	0.5776	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:05	FQWQEKLKLTY	0.994	0.9087	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:31	FQWQEKLKLTY	0.9902	0.9192	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C15:05	TTFQWQEKL	0.9974	0.9124	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C15:02	TTFQWQEKL	0.9969	0.8362	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C15:09	TTFQWQEKL	0.9966	0.8313	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:125	WQEKLKLTY	0.9957	0.762	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:34	WQEKLKLTY	0.9957	0.762	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:33	WQEKLKLTY	0.9957	0.762	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:27	WQEKLKLTY	0.9955	0.7664	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:135	WQEKLKLTY	0.9952	0.7519	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:50	WQEKLKLTY	0.9951	0.8558	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B27:06	FQWQEKLKL	0.9912	0.7473	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:12	WQEKLKLTY	0.9841	0.7861	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A68:02	TTFQWQEKL	0.9837	0.7896	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B27:09	FQWQEKLKL	0.9799	0.8803	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:24	WQEKLKLTY	0.9733	0.7654	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:14	FQWQEKLKL	0.9674	0.6738	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A02:06	FQWQEKLKL	0.9669	0.7151	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C04:04	FQWQEKLKL	0.9645	0.9115	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:03	FQWQEKLKL	0.9606	0.9945	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:04	FQWQEKLKL	0.9606	0.9945	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:35	WQEKLKLTY	0.9515	0.698	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A69:01	TTFQWQEKL	0.9474	0.6309	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:04	FQWQEKLKL	0.9399	0.9448	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C17:01	FQWQEKLKL	0.9337	0.9388	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C06:02	FQWQEKLKL	0.9265	0.9912	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C06:17	FQWQEKLKL	0.9265	0.9912	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:24	FQWQEKLKL	0.9153	0.9267	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:05	FQWQEKLKL	0.9128	0.9592	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C06:06	FQWQEKLKL	0.9117	0.9873	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:02	FQWQEKLKL	0.8998	0.9783	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:06	FQWQEKLKL	0.8887	0.9953	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C03:67	FQWQEKLKL	0.8868	0.9902	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:53	WQEKLKLTY	0.8846	0.7038	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:73	FQWQEKLKL	0.8787	0.8478	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C07:17	FQWQEKLKL	0.8763	0.9795	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:39	WQEKLKLTY	0.8759	0.7634	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C08:01	FQWQEKLKL	0.8589	0.989	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-A32:01	TTFQWQEKL	0.8423	0.9507	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:31	FQWQEKLKL	0.8156	0.9632	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:02	FQWQEKLKL	0.8134	0.9584	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:04	WQEKLKLTY	0.8069	0.8729	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C06:08	FQWQEKLKL	0.8007	0.9794	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:20	WQEKLKLTY	0.7604	0.9025	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:30	FQWQEKLKL	0.741	0.9216	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:08	WQEKLKLTY	0.7371	0.7496	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B39:11	FQWQEKLKL	0.7363	0.9333	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:07	WQEKLKLTY	0.7338	0.7796	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:68	FQWQEKLKL	0.7335	0.7399	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:06	WQEKLKLTY	0.7314	0.8563	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:53	FQWQEKLKL	0.7242	0.9084	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C02:10	FQWQEKLKL	0.7211	0.9606	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C02:02	FQWQEKLKL	0.7211	0.9606	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:05	WQEKLKLTY	0.7159	0.8532	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B38:05	FQWQEKLKL	0.7142	0.9835	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B35:28	WQEKLKLTY	0.7139	0.9032	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:54	FQWQEKLKL	0.7061	0.8958	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:03	WQEKLKLTY	0.698	0.8353	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B35:20	WQEKLKLTY	0.6402	0.9227	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:54	WQEKLKLTY	0.6287	0.67	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B18:11	WQEKLKLTY	0.6168	0.8784	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B35:13	FQWQEKLKL	0.4933	0.9629	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B48:02	FQWQEKLKL	0.4407	0.9653	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:13	WQEKLKLTY	0.3662	0.7218	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B48:02	WQEKLKLTY	0.3494	0.8846	11	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-C17:01	TTFQWQEKL	0.3247	0.9569	7	16
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:09	FQWQEKLKL	0.3238	0.812	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:20	FQWQEKLKL	0.3013	0.9708	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B35:28	FQWQEKLKL	0.2962	0.9722	9	18
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:12	QWQEKLKLTY	0.9606	0.6478	10	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:20	QWQEKLKLTY	0.8249	0.9229	10	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B35:28	QWQEKLKLTY	0.8	0.9249	10	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:135	FQWQEKLKLTY	1	0.8174	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:125	FQWQEKLKLTY	1	0.8179	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:50	FQWQEKLKLTY	1	0.8023	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:33	FQWQEKLKLTY	1	0.8179	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:34	FQWQEKLKLTY	1	0.8179	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:27	FQWQEKLKLTY	1	0.8124	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:24	FQWQEKLKLTY	0.9999	0.8525	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:35	FQWQEKLKLTY	0.9999	0.7792	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:12	FQWQEKLKLTY	0.9999	0.7916	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:53	FQWQEKLKLTY	0.9997	0.7736	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:54	FQWQEKLKLTY	0.9997	0.7474	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:39	FQWQEKLKLTY	0.9987	0.8293	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B15:20	FQWQEKLKLTY	0.994	0.9487	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B35:28	FQWQEKLKLTY	0.992	0.9502	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B35:20	FQWQEKLKLTY	0.9884	0.958	9	20
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	238	HLA-B48:02	FQWQEKLKLTY	0.9619	0.9385	9	20

Top

Potential FusionNeoAntigen Information of AKT3-SDCCAG8 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of AKT3-SDCCAG8

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
9125	STTFQWQEKLKLTY	AKT3	SDCCAG8	chr1	243858893	chr1	243468015	238

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AKT3-SDCCAG8

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	9125	STTFQWQEKLKLTY	-7.15543	-7.26883
HLA-B14:02	3BVN	9125	STTFQWQEKLKLTY	-4.77435	-5.80965
HLA-B52:01	3W39	9125	STTFQWQEKLKLTY	-6.80875	-6.92215
HLA-B52:01	3W39	9125	STTFQWQEKLKLTY	-4.20386	-5.23916
HLA-A11:01	4UQ2	9125	STTFQWQEKLKLTY	-7.5194	-8.5547
HLA-A11:01	4UQ2	9125	STTFQWQEKLKLTY	-6.9601	-7.0735
HLA-A24:02	5HGA	9125	STTFQWQEKLKLTY	-7.52403	-7.63743
HLA-A24:02	5HGA	9125	STTFQWQEKLKLTY	-5.82433	-6.85963
HLA-B27:05	6PYJ	9125	STTFQWQEKLKLTY	-3.28285	-4.31815
HLA-B44:05	3DX8	9125	STTFQWQEKLKLTY	-5.91172	-6.94702
HLA-B44:05	3DX8	9125	STTFQWQEKLKLTY	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of AKT3-SDCCAG8

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	10	20	QWQEKLKLTY	CAGTGGCAAGAGAAGCTAAAACTTACTTAT
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	11	20	WQEKLKLTY	TGGCAAGAGAAGCTAAAACTTACTTAT
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	7	16	TTFQWQEKL	ACAACTTTTCAGTGGCAAGAGAAGCTA
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	7	18	TTFQWQEKLKL	ACAACTTTTCAGTGGCAAGAGAAGCTAAAACTT
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	8	18	TFQWQEKLKL	ACTTTTCAGTGGCAAGAGAAGCTAAAACTT
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	9	18	FQWQEKLKL	TTTCAGTGGCAAGAGAAGCTAAAACTT
AKT3-SDCCAG8	chr1	243858893	chr1	243468015	9	20	FQWQEKLKLTY	TTTCAGTGGCAAGAGAAGCTAAAACTTACTTAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of AKT3-SDCCAG8

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
Non-Cancer	AKT3-SDCCAG8	chr1	243858893	ENST00000336199	chr1	243468015	ENST00000343783	TCGA-IN-8462-11A

Top

Potential target of CAR-T therapy development for AKT3-SDCCAG8

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to AKT3-SDCCAG8

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to AKT3-SDCCAG8

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)